Previous Pause Next
Home >> News Center >>
Clinical Trials
4SC's Resminostat Meets Primary Efficacy Endpoint in Phase II Trial in Hodgkin's Lymphoma (HL) PDF Print E-mail
Tuesday, 06 September 2011 01:48

4SC AG (FWB:VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma (HL).

Read more...
 
Mesoblast Receives Clearance To Begin First European Trial Of Allogeneic Or 'Off-The-Shelf' Stem Cell Treatment For Heart Attacks PDF Print E-mail
Tuesday, 06 September 2011 01:45
Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to preventheart failure after a major heart attack.
Read more...
 
ZIOPHARM Oncology, Inc. (ZIOP.OB) Announces First Patient Dosed in Phase I Study of ZIN ATI-001 in Advanced Melanoma PDF Print E-mail
Saturday, 03 September 2011 23:34

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma.

Read more...
 
MorphoSys AG Doses First Patient in Phase 1/2a Clinical Trial for MOR202 Program in Multiple Myeloma PDF Print E-mail
Saturday, 03 September 2011 23:29

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the first patient in a Phase 1/2a clinical trial of its cancer antibody MOR202 has been dosed.

Read more...
 
Infectious Disease Specialists Report a Higher Trial Rate for Forest/Astrazeneca’s Ceftaroline Compared to Internists Who Are Likely to Be Late Adopters of This Novel Therapy According to Results from a New LaunchTrends Institutional Study PDF Print E-mail
Friday, 02 September 2011 01:26

Arlington Medical Resources (AMR) and BioTrends Research Group find that unaided awareness of and familiarity with Teflaro is extremely high among infectious disease (ID) specialists at three months post-launch with more than one-third of surveyed participants report having already initiated trial of Teflaro.

Read more...
 
Dr. Reddy’s Announces Start of Phase II Study with the CETP Inhibitor, DRL-17822 in Dyslipidemia Patients PDF Print E-mail
Friday, 02 September 2011 01:22

Dr. Reddy’s Laboratories (NYSE: RDY) announced the initiation of dosing with DRL-17822 in patients with diagnosis of type II dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.

Read more...
 
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Commencement Of Investigator-Initiated Phase 2 Trial Of Sapacitabine In Patients With CLL Or SLL Hematological Malignancies And 11q22-23 Deletion PDF Print E-mail
Thursday, 01 September 2011 00:41

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that the first patient has been dosed in an investigator-initiated, translational, Phase 2 clinical study at The University of Texas MD Anderson Cancer Center.

Read more...
 
Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers PDF Print E-mail
Thursday, 01 September 2011 00:31

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has completed recruitment in a Phase IIb clinical trial designed to investigate KUR-211 (Viz.I-020201) in the treatment of diabetic foot ulcers.

Read more...
 
Public Disclosure Of Clinical Trial Results By Health Canada Should Be Mandatory PDF Print E-mail
Wednesday, 31 August 2011 00:58

Health Canada is not prevented by law from publicly disclosing safety and efficacy data from clinical trials, pharmaceuticals, biologics and medical devices and should be more transparent, states an analysis in CMAJ (Canadian Medical Association Journal)

Read more...
 
ZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of ZIN ATI-001 in Advanced Melanoma PDF Print E-mail
Wednesday, 31 August 2011 00:54

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma. ZIN ATI-001 is the second clinical oncology product candidate from the ZIOPHARM-Intrexon Corporation exclusive synthetic biology channel partnership.

Read more...
 
NOXXON initiates Phase I of NOX-H94 for Anemia of Chronic Disease PDF Print E-mail
Tuesday, 06 September 2011 01:46

NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company’s third compound to enter the clinic.

Read more...
 
Chugai Initiates Clinical Trials For Multiple In-Licensed Compounds Utilizing The Personalized Healthcare Strategy PDF Print E-mail
Tuesday, 06 September 2011 01:44
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, "Chugai")] announced that it has entered into license agreements with F. Hoffmann-La Roche, Ltd [Head Office: Basel, Switzerland / CEO: Severin Schwan (hereafter, "Roche")] covering humanized anti-Met antibody MetMAb, for non-small celllung cancer (NSCLC) and humanized anti-interleukin(IL)-13 antibody lebrikizumab for bronchial asthma which are both currently developed by Roche utilizing the Personalized Healthcare (PHC) approach and have also entered phase I clinical studies in the Japanese population.
Read more...
 
Shire plc Presents Positive Data from Fabry and Gaucher Disease Studies that Continue to Support Patient Switches to REPLAGAL(R) (agalsidase alfa) and VPRIV(R) (velaglucerase alfa) PDF Print E-mail
Saturday, 03 September 2011 23:32

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced positive data from several studies designed to evaluate the safety of switching to REPLAGAL (agalsidase alfa) from Fabrazyme® (agalsidase beta) and the long-term safety and benefits of switching to VPRIV (velaglucerase alfa) from Cerezyme® (imiglucerase).

Read more...
 
Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent PDF Print E-mail
Saturday, 03 September 2011 23:26

 

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that, in consultation with the U.S. Food and Drug Administration (FDA), the company will amend the design of ongoing clinical trials to discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.
Read more...
 
Resverlogix Presents Two Abstracts on Analysis of the Phase 2 ASSERT Clinical Trial at The ESC Congress 2011 PDF Print E-mail
Friday, 02 September 2011 01:24

Resverlogix Corp. ("Resverlogix") (TSX: RVX) announced today that two abstracts on the analysis of the ASSERT trial were presented at the European Society of Cardiology (ESC) Congress 2011 in Paris, France.

Read more...
 
Aeterna Zentaris Announces Completion Of Interim Analysis By Data Safety Monitoring Board For The Phase 3 Study Of Perifosine For Colorectal Cancer PDF Print E-mail
Friday, 02 September 2011 01:20
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced that the independent Data Safety Monitoring Board (DSMB) for the pivotal Phase 3 X-PECT study of perifosine in patients with refractory advancedcolorectal cancer has completed a pre-specified interim analysis for safety and futility.
Read more...
 
Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ PDF Print E-mail
Thursday, 01 September 2011 00:39

Pharmaceutical company Hatchtech Pty Ltd has completed treatment of subjects for its Phase 2b clinical study to confirm the efficacy of its novel head lice treatment DeOvo™.

Read more...
 
Pearl Therapeutics Announces Positive Results For Phase 2b Dose-Ranging Study Of Formoterol MDI PDF Print E-mail
Thursday, 01 September 2011 00:28
Pearl Therapeutics Inc. announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil® Aerolizer® in patients with moderate-to-severe COPD.
Read more...
 
PHT Corporation’s Enhanced SmartReports™ Dramatically Improves Clinical Trial Data Reporting for Project Managers, Monitors and Sites PDF Print E-mail
Wednesday, 31 August 2011 00:56

PHT Corporation continues to make clinical trial patient data reports more available and versatile for clinical trial stakeholders with an enhanced version of SmartReports within StudyWorks™, its online clinical patient data reporting system.

Read more...
 
Aeterna Zentaris Reports Positive Phase III Results for AGHD Test PDF Print E-mail
Wednesday, 31 August 2011 00:52

Aeterna Zentaris reported favorable top-line results of its completed Phase III study with AEZS-130 as the first oral diagnostic test for adult growth hormone deficiency (AGHD).

Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 10 of 122